Iskalni niz:
išči po
išči po
išči po
išči po
Vrsta gradiva:
Jezik:
Št. zadetkov: 7
Zdravstvena nega bolnika na zdravljenju z radioterapijo in kombiniranem zdravljenju ob odpustu iz bolnišnice ter pri ambulantni obravnavi
Helena Avsec
Objavljeni strokovni prispevek na konferenci
Oznake:
Zdravstvena nega bolnika na zdravljenju z radioterapijo in kombiniranem zdravljenju ob odpustu iz bolnišnice ter pri ambulantni obravnavi
Leto: 2006 Vir: Onkološki inštitut Ljubljana (OI)
Učinkovitost negovalnih prehranskih intervencij pri hospitaliziranih pacientih z rakom glave in vratu
Biserka Petrijevčanin, Helena Avsec, Ana Istenič, Denis Mlakar-Mastnak
Objavljeni strokovni prispevek na konferenci
Oznake:
Učinkovitost negovalnih prehranskih intervencij pri hospitaliziranih pacientih z rakom glave in vratu
Leto: 2008 Vir: Onkološki inštitut Ljubljana (OI)
The role of proteasome, immunoproteasome and autophagy in the therapy of chronic lymphocytic leukemia
Damjan Avsec, Irena Mlinarič Raščan, Helena Podgornik
Doktorska disertacija
Oznake: CLL;proteasome;immunoproteasome;autophagy;targeted therapy;resistance;ibrutinib;idelalisib;venetoclax;NFκB;B-cell receptor;
Chronic lymphocytic leukemia (CLL) is a disease of accumulating malignant mature-appearing monoclonal B-lymphocytes in blood, bone marrow, and lymphatic tissues. The incidence of CLL in Slovenia is among the Europe’s highest, and with current demographic changes the burden of the disease is expected ...
Leto: 2023 Vir: Fakulteta za farmacijo (UL FFA)
ǂThe ǂenhanced cytotoxic effects in B-cell leukemia and lymphoma following activation of prostaglandin EP4 receptor and targeting of CD20 antigen by monoclonal antibodies
Tijana Markovič, Helena Podgornik, Damjan Avsec, Sanja Vrbek, Irena Mlinarič-Raščan, Irena Mlinarič-Raščan
Izvirni znanstveni članek
Oznake: B-cell leukemia and lymphoma;chronic lymphocytic leukemia;prostaglandin EP4 receptor;selective EP4 receptor agonist;monoclonal antibodies;synergistic effects;
Anti-CD20 monoclonal antibodies (MAbs) have revolutionized the treatment of B-cell leukemia and lymphoma. However, many patients do not respond to such treatment due to either deficiency of the complementary immune response or resistance to apoptosis. Other currently available treatments are often i ...
Leto: 2022 Vir: Fakulteta za farmacijo (UL FFA)
EP4 receptor agonist L-902688 augments cytotoxic activities of ibrutinib, idelalisib, and venetoclax against chronic lymphocytic leukemia cells
Sanja Vrbek, Tijana Markovič, Damjan Avsec, Martina Gobec, Helena Podgornik, Žiga Jakopin, Irena Mlinarič-Raščan
Izvirni znanstveni članek
Oznake: chronic lymphocytic leukemia;L-902688;NF-{kappa]B inhibition;prostaglandin E4;receptor;synergistic cytotoxic activity;
Treatment of patients with relapsed or refractory chronic lymphocytic leukemia (CLL) has significantly improved more recently with the approval of several new agents, including ibrutinib, idelalisib, and venetoclax. Despite the outstanding efficacies observed with these agents, these treatments are ...
Leto: 2021 Vir: Fakulteta za farmacijo (UL FFA)
Inhibition of p38 MAPK or immunoproteasome overcomes resistance of chronic lymphocytic leukemia cells to Bcl-2 antagonist venetoclax
Damjan Avsec, Marja Škrlj, Tilen Burnik, Maša Kandušer, Maruša Rajh, Helena Podgornik, Irena Mlinarič-Raščan
Izvirni znanstveni članek
Oznake:
Chronic lymphocytic leukemia (CLL) is a hematological neoplasm of CD19-positive mature-appearing B lymphocytes. Despite the clinical success of targeted therapies in CLL, the development of resistance diminishes their therapeutic activity. This is also true for the Bcl-2 antagonist venetoclax. We in ...
Leto: 2022 Vir: Fakulteta za farmacijo (UL FFA)
Targeting autophagy triggers apoptosis and complements the action of venetoclax in chronic lymphocytic leukemia cells
Damjan Avsec, Alma Tana Jakoš Djordjevič, Maša Kandušer, Helena Podgornik, Matevž Škerget, Irena Mlinarič-Raščan
Izvirni znanstveni članek
Oznake: avtofagi;odpornost na zdravila;tarčna terapija;chronic lymphocytic leukemia;autophagy;AMPK/ULK1;venetoclax;drug resistance;targeted therapy;
Continuous treatment of patients with chronic lymphocytic leukemia (CLL) with venetoclax, an antagonist of the anti-apoptotic protein Bcl-2, can result in resistance, which highlights the need for novel targets to trigger cell death in CLL. Venetoclax also induces autophagy by perturbing the Bcl-2/B ...
Leto: 2021 Vir: Fakulteta za farmacijo (UL FFA)
Št. zadetkov: 7
Ključne besede:
Leto izdaje:
Avtorji:
Repozitorij:
Tipologija:
Jezik: